Bacteria as vectors for gene therapy of cancer

Anti-cancer therapy faces major challenges, particularly in terms of specificity of treatment. The ideal therapy would eradicate tumour cells selectively with minimum side effects on normal tissue. Gene or cell therapies have emerged as realistic prospects for the treatment of cancer, and involve the delivery of genetic information to a tumour to facilitate the production of therapeutic proteins. However, there is still much to be done before an efficient and safe gene medicine is achieved, primarily developing the means of targeting genes to tumours safely and efficiently. An emerging family of vectors involves bacteria of various genera. It has been shown that bacteria are naturally capable of homing to tumours when systemically administered resulting in high levels of replication locally. Furthermore, invasive species can deliver heterologous genes intra-cellularly for tumour cell expression. Here, we review the use of bacteria as vehicles for gene therapy of cancer, detailing the mechanisms of action and successes at preclinical and clinical levels.

[1]  Michelle Cronin,et al.  A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. , 2010, Human gene therapy.

[2]  C. Hormaeche Live attenuated Salmonella vaccines and their potential as oral combined vaccines carrying heterologous antigens. , 1991, Journal of immunological methods.

[3]  J. Letesson,et al.  Yersinia enterocolitica as a Vehicle for a Naked DNA Vaccine Encoding Brucella abortus Bacterioferritin or P39 Antigen , 2002, Infection and Immunity.

[4]  P. Lambin,et al.  Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum , 2001, Cancer Gene Therapy.

[5]  L. Wood,et al.  Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. , 2010, Seminars in immunology.

[6]  M. Svoboda Culturing Cancer in the American Century , 1999 .

[7]  Y-F Xu,et al.  A new expression plasmid in Bifidobacterium longum as a delivery system of endostatin for cancer gene therapy , 2007, Cancer Gene Therapy.

[8]  Rachel W. Kasinskas,et al.  Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. , 2007, Cancer research.

[9]  M. Tangney,et al.  Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease , 2006, Cancer Immunology, Immunotherapy.

[10]  Miles Irving,et al.  Bailey & Love's Short Practice of Surgery , 1966 .

[11]  Y. Huang,et al.  Oral delivery of tumor‐targeting Salmonella for cancer therapy in murine tumor models , 2007, Cancer science.

[12]  M. Sznol,et al.  Use of preferentially replicating bacteria for the treatment of cancer. , 2000, The Journal of clinical investigation.

[13]  J. Pawelek,et al.  Tumor-Targeted Salmonella , 2002 .

[14]  Qian Zhang,et al.  Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins , 2004, Nature Biotechnology.

[15]  M. Hung,et al.  An attenuated Salmonella oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express α-fetoprotein , 2006, Cancer Gene Therapy.

[16]  Yan Yin,et al.  Therapeutic efficacy of Bifidobacterium longum‐mediated human granulocyte colony‐stimulating factor and/or endostatin combined with cyclophosphamide in mouse‐transplanted tumors , 2009, Cancer science.

[17]  M. Tangney,et al.  Genetic Vaccines and Therapy , 2009 .

[18]  I. Charles,et al.  Use of live attenuated bacteria to stimulate immunity. , 1990, Research in microbiology.

[19]  D. Pardoll,et al.  GM-CSF-based cellular vaccines: a review of the clinical experience. , 2002, Cytokine & growth factor reviews.

[20]  N. Senzer,et al.  Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients , 2003, Cancer Gene Therapy.

[21]  D. Kopecko,et al.  Bacterial delivery of siRNAs: a new approach to solid tumor therapy. , 2009, Methods in molecular biology.

[22]  P. Sweeney,et al.  Optimised electroporation mediated DNA vaccination for treatment of prostate cancer , 2010, Genetic vaccines and therapy.

[23]  D. Gericke,et al.  ONCOLYSIS BY CLOSTRIDIA. II. EXPERIMENTS ON A TUMOR SPECTRUM WITH A VARIETY OF CLOSTRIDIA IN COMBINATION WITH HEAVY METAL. , 1964, Cancer research.

[24]  Ying Huang,et al.  Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma , 2005, Acta Pharmacologica Sinica.

[25]  Ines S. Jaeger,et al.  Survivin minigene DNA vaccination is effective against neuroblastoma , 2009, International journal of cancer.

[26]  K. Timmis,et al.  Oral Somatic Transgene Vaccination Using Attenuated S. typhimurium , 1997, Cell.

[27]  Yayi Hou,et al.  Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer , 2005, Cancer Gene Therapy.

[28]  W. Goebel,et al.  Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery , 2003, Gene Therapy.

[29]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Cusack,et al.  Introduction to cancer gene therapy. , 2002, Surgical oncology clinics of North America.

[31]  P. Celec,et al.  Bacteria in gene therapy: bactofection versus alternative gene therapy , 2006, Gene Therapy.

[32]  S. Dunstan,et al.  Comparison of the Abilities of Different AttenuatedSalmonella typhimurium Strains To Elicit Humoral Immune Responses against a Heterologous Antigen , 1998, Infection and Immunity.

[33]  W. Goebel,et al.  Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes , 1998, Nature Biotechnology.

[34]  M. Tangney,et al.  Sonoporation mediated immunogene therapy of solid tumors. , 2010, Ultrasound in medicine & biology.

[35]  Werner Goebel,et al.  Comparison of Different Live Vaccine Strategies In Vivo for Delivery of Protein Antigen or Antigen-Encoding DNA and mRNA by Virulence-Attenuated Listeria monocytogenes , 2006, Infection and Immunity.

[36]  Donald W Kufe,et al.  Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Hill,et al.  Improved Luciferase Tagging System for Listeria monocytogenes Allows Real-Time Monitoring In Vivo and In Vitro , 2007, Applied and Environmental Microbiology.

[38]  S. McKenna,et al.  Evaluation of cellular uptake and gene transfer efficiency of pegylated poly-L-lysine compacted DNA: implications for cancer gene therapy. , 2006, Molecular pharmaceutics.

[39]  Peter Lee Biocontainment strategies for live lactic acid bacteria vaccine vectors , 2010, Bioengineered bugs.

[40]  Meng Yang,et al.  Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Maciag,et al.  A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors , 2009, Clinical Cancer Research.

[42]  John Calvin Reed,et al.  Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth , 2007, Proceedings of the National Academy of Sciences.

[43]  John Calvin Reed,et al.  Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand , 2008, Journal of the National Cancer Institute.

[44]  W. König,et al.  Further progress with oncolysis due to apathogenic clostridia. , 1979, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie.

[45]  S. Weiss,et al.  Bacteria-mediated DNA transfer in gene therapy and vaccination , 2004, Expert opinion on biological therapy.

[46]  John Mao,et al.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Gengfeng Fu,et al.  Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective inhibitor of angiogenesis and hypoxic tumor growth , 2003, Cancer Gene Therapy.

[48]  L. Kou,et al.  Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth , 2009, Cancer Gene Therapy.

[49]  F. Heppner,et al.  The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium , 2005, Acta Neurochirurgica.

[50]  Takayuki Sasaki,et al.  Cloned Cytosine Deaminase Gene Expression of Bifidobacterium longum and Application to Enzyme/Pro-drug Therapy of Hypoxic Solid Tumors , 2002, Bioscience, biotechnology, and biochemistry.

[51]  M. Samoszuk,et al.  Improved Immunohistochemical Method for Detecting Hypoxia Gradients in Mouse Tissues and Tumors , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[52]  J. Fallon,et al.  A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. , 2008, Journal of the National Cancer Institute.

[53]  R. C. Parker,et al.  Effect of Histolyticus Infection and Toxin on Transplantable Mouse Tumors.∗ , 1947, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[54]  S. H. Kim,et al.  Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases , 2008, British Journal of Cancer.

[55]  Y. Huang,et al.  Oral delivery of tumor‐targeting Salmonella exhibits promising therapeutic efficacy and low toxicity , 2009, Cancer science.

[56]  M. Moreno,et al.  Salmonella as live trojan horse for vaccine development and cancer gene therapy. , 2010, Current gene therapy.

[57]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[58]  K. Lundstrom Latest development in viral vectors for gene therapy. , 2003, Trends in biotechnology.

[59]  AJ Giaccia,et al.  Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis , 2002, Gene Therapy.

[60]  Michelle Cronin,et al.  Development of a luciferase-based reporter system to monitor Bifidobacterium breve UCC2003 persistence in mice , 2008, BMC Microbiology.

[61]  C. Lewis,et al.  Use of bacteria in anti-cancer therapies. , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[62]  Z. Hua,et al.  Enhanced therapeutic effect by combination of tumor-targeting salmonella and endostatin in murine melanoma model , 2005, Cancer biology & therapy.

[63]  P. Maciag,et al.  Construction and Characterization of an Attenuated Listeria monocytogenes Strain for Clinical Use in Cancer Immunotherapy , 2008, Clinical and Vaccine Immunology.

[64]  J. Sadoff,et al.  Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization , 1995, Science.

[65]  E. Jaffee,et al.  Fusion to Listeriolysin O and Delivery by Listeria monocytogenes Enhances the Immunogenicity of HER-2/neu and Reveals Subdominant Epitopes in the FVB/N Mouse1 , 2005, The Journal of Immunology.

[66]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[67]  F. Heffron,et al.  Identification of Three Highly Attenuated Salmonella typhimurium Mutants That Are More Immunogenic and Protective in Mice than a Prototypical aroA Mutant , 1998, Infection and Immunity.

[68]  H. O'brodovich,et al.  Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer , 1999, Gene Therapy.

[69]  J. Pawelek,et al.  Bacteria as tumour-targeting vectors. , 2003, The Lancet. Oncology.

[70]  D. Bermudes,et al.  Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy. , 2009, Methods in molecular biology.

[71]  J. Fruehauf,et al.  Engineered E. coli as vehicles for targeted therapeutics. , 2010, Current gene therapy.

[72]  P. Cossart,et al.  Internalin-expressing Lactococcus lactis is able to invade small intestine of guinea pigs and deliver DNA into mammalian epithelial cells. , 2005, Microbes and infection.

[73]  J. Sadoff,et al.  Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells , 1990, The Journal of experimental medicine.

[74]  X. Luo,et al.  Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[75]  J. Moese,et al.  ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA. , 1964, Cancer research.

[76]  M. Belcourt,et al.  Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. , 2002, Human gene therapy.

[77]  F. Dietzel Basic principles in hyperthermic tumor therapy. , 1983, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[78]  M. Cronin,et al.  Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  H. Schatten,et al.  Salmonella–Host Cell Interactions, Changes in Host Cell Architecture, and Destruction of Prostate Tumor Cells with Genetically Altered Salmonella , 2007, Microscopy and Microanalysis.

[80]  G. Vassaux,et al.  Recombinant Escherichia coli expressing invasin targets the Peyer's patches: the basis for a bacterial formulation for oral vaccination. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[81]  P. Maciag,et al.  Development of a Listeria monocytogenes based vaccine against prostate cancer , 2008, Cancer Immunology, Immunotherapy.

[82]  A. Miller,et al.  Non–invasive liposome–mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice , 1993 .

[83]  M. Małecki,et al.  Angiogenic and antiangiogenic gene therapy , 2005, Gene Therapy.

[84]  L. Ellis,et al.  Phase I study of recombinant human endostatin in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  F. Graham,et al.  Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. , 1999, Human gene therapy.

[86]  R. Preissner,et al.  A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity , 2008, Molecular Cancer Therapeutics.

[87]  A. Shiau,et al.  Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model , 2005, Cancer Gene Therapy.

[88]  M. Wei,et al.  Bacterial targeted tumour therapy-dawn of a new era. , 2008, Cancer letters.

[89]  N. Forbes,et al.  Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice , 2009, British Journal of Cancer.

[90]  E. Ko,et al.  Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A , 2003, Cancer Gene Therapy.

[91]  G. Yang,et al.  Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model , 1999, Gene Therapy.

[92]  D. Ren,et al.  Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2′-deoxyriboside via Salmonella against murine tumors , 2008, Cancer Gene Therapy.

[93]  P Lambin,et al.  Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo , 2006, British Journal of Cancer.

[94]  Shibin Zhou Combination therapy with bacteria and angiogenesis inhibitors: Strangling cancer without mercy , 2005, Cancer biology & therapy.

[95]  Jack D Bui,et al.  Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? , 2007, Current opinion in immunology.

[96]  W. Goebel,et al.  Bacterial delivery of functional messenger RNA to mammalian cells , 2005, Cellular microbiology.

[97]  Li-shan Chen,et al.  Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic , 2008, Cancer biology & therapy.

[98]  S. Radulović,et al.  The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. , 2009, Vaccine.

[99]  John Calvin Reed,et al.  Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth , 2009, Cancer Immunology, Immunotherapy.

[100]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[101]  M. Hashida,et al.  The Fate of Plasmid DNA After Intravenous Injection in Mice: Involvement of Scavenger Receptors in Its Hepatic Uptake , 1995, Pharmaceutical Research.

[102]  Panos Lehouritis,et al.  Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy , 2008, Clinical Cancer Research.

[103]  A. Giaccia,et al.  Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. , 1996, Gene therapy.

[104]  Bert Vogelstein,et al.  Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[105]  Robert Preissner,et al.  Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. , 2006, Cancer research.

[106]  H. Hricak,et al.  Escherichia coli Nissle 1917 Facilitates Tumor Detection by Positron Emission Tomography and Optical Imaging , 2008, Clinical Cancer Research.

[107]  N. Habib Cancer Gene Therapy: Past Achievements and Future Challenges , 2002 .

[108]  X. Luo,et al.  Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. , 2001, Oncology research.

[109]  S. S. Hall A Commotion in the Blood: Life, Death, and the Immune System , 1997 .

[110]  Mark Tangney,et al.  Tumour targeting with systemically administered bacteria. , 2010, Current gene therapy.

[111]  J. Pawelek,et al.  Tumor-targeted Salmonella. Highly selective delivery vectors. , 2000, Advances in experimental medicine and biology.

[112]  M. Tangney,et al.  Listeria monocytogenes as a vector for anti-cancer therapies. , 2010, Current gene therapy.

[113]  D. Gericke,et al.  ONCOLYSIS BY CLOSTRIDIA. V. TRANSPLANTED TUMORS OF THE HAMSTER. , 1964, Cancer research.

[114]  N. Lemoine,et al.  Bacterial gene therapy strategies , 2006, The Journal of pathology.

[115]  M. Tangney,et al.  The use of Listeria monocytogenes as a DNA delivery vector for cancer gene therapy , 2010, Bioengineered bugs.

[116]  R. Blasberg,et al.  Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK , 2005, Cancer Gene Therapy.

[117]  P. Courvalin,et al.  Gene transfer from bacteria to mammalian cells. , 1995, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[118]  R. Webster,et al.  DNA vaccines. , 1996, AIDS research and human retroviruses.

[119]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[120]  M. Tangney,et al.  Viral vectors in cancer immunotherapy: which vector for which strategy? , 2008, Current gene therapy.

[121]  M. Colombo,et al.  Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. , 1998, Blood.

[122]  J. Nemunaitis,et al.  A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. , 2001, Human gene therapy.

[123]  John Calvin Reed,et al.  IL-18-producing Salmonella inhibit tumor growth , 2008, Cancer Gene Therapy.

[124]  E. Hohmann,et al.  Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. , 2006, Vaccine.